AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26932780 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion (ABT) device
Number of subjects: 229
Study 26932780 — intervention group
Group type: COMPARATOR
Intervention: High-vacuum drainage
Number of subjects: 229
Study 26932780 — intervention group
Group type: EXPERIMENTAL
Intervention: Retransfusion (among those who received it)
Number of subjects: 229
Study 24678979 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab (420 mg) every 4 weeks
Number of subjects: 901
Study 24678979 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab (420 mg) with background therapy of diet alone
Number of subjects: 901
Study 24678979 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab (420 mg) with background therapy of atorvastatin 10 mg
Number of subjects: 901
Study 24678979 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab (420 mg) with background therapy of atorvastatin 80 mg
Number of subjects: 901
Study 24678979 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab (420 mg) with background therapy of atorvastatin 80 mg plus ezetimibe 10 mg
Number of subjects: 901
Study 24678979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 901
Study 22948387 — intervention group
Group type: COMPARATOR
Intervention: Cefepime (CFPM, control)
Number of subjects: 255
Study 22948387 — intervention group
Group type: EXPERIMENTAL
Intervention: Panipenem/betamiprom (PAPM/BP)
Number of subjects: 255
Study 22948387 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM)
Number of subjects: 255
Study 22948387 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (CPFX)
Number of subjects: 255
Study 22948387 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglycosides (AGs)
Number of subjects: 255
Study 20357810 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-education instruction (TI)
Number of subjects: 48
Study 20357810 — intervention group
Group type: COMPARATOR
Intervention: Classroom teaching (CT)
Number of subjects: 48
Study 17451909 — intervention group
Group type: EXPERIMENTAL
Intervention: Model package inserts
Number of subjects: 1105
Study 17451909 — intervention group
Group type: COMPARATOR
Intervention: Original package inserts
Number of subjects: 1105
Study 15136775 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity supervised aerobic exercise program (n = 15)
Number of subjects: 31
Study 15136775 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 16)
Number of subjects: 31
Study 11478556 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 0
Study 11478556 — intervention group
Group type: COMPARATOR
Intervention: Taping (Conservative management)
Number of subjects: 0
Study 9749682 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 21
Study 9749682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 8147547 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dopamine (3 micrograms/kg per minute)
Number of subjects: 37
Study 8147547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 3171029 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamphlets only
Number of subjects: 73
Study 3171029 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing follow-up
Number of subjects: 73
Study 3171029 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained volunteer follow-up
Number of subjects: 73
Study 3171029 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients on another medical floor)
Number of subjects: 73
Study 31461862 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic‐index pulse‐based diet
Number of subjects: 6
Study 31461862 — intervention group
Group type: COMPARATOR
Intervention: Typical hospital diet
Number of subjects: 6
Study 29940914 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle advice alongside estimated 10-year risk of developing cancer presented in bar chart format
Number of subjects: 1000
Study 29940914 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle advice alongside estimated 10-year risk of developing cancer presented in pictograph format
Number of subjects: 1000
Study 29940914 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle advice alongside estimated 10-year risk of developing cancer presented in qualitative scale format
Number of subjects: 1000
Study 29940914 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving cancer-specific lifestyle advice alone
Number of subjects: 1000
Study 29940914 — intervention group
Group type: EXPERIMENTAL
Intervention: All intervention groups
Number of subjects: 1000
Study 26453814 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS distortion in two or more leads (D2+)
Number of subjects: 174
Study 26453814 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS distortion in one lead (D1)
Number of subjects: 174
Study 26453814 — intervention group
Group type: COMPARATOR
Intervention: No QRS distortion (D0)
Number of subjects: 174
Study 24597469 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Treatment (IT)
Number of subjects: 76
Study 24597469 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control Group)
Number of subjects: 76
Study 22026455 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (1111-6800 IU/day)
Number of subjects: 569
Study 22026455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 569
Study 20565953 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel followed by anthracyclines (Arm A)
Number of subjects: 60
Study 20565953 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs in reverse order (Arm B)
Number of subjects: 60
Study 17407241 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-blocking drug
Number of subjects: 30
Study 17407241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 17407241 — intervention group
Group type: EXPERIMENTAL
Intervention: Berlin method
Number of subjects: 30
Study 17407241 — intervention group
Group type: EXPERIMENTAL
Intervention: SPARCC scoring system
Number of subjects: 30
Study 17407241 — intervention group
Group type: EXPERIMENTAL
Intervention: ASspiMRI-a
Number of subjects: 30
Study 17407241 — intervention group
Group type: EXPERIMENTAL
Intervention: All methods
Number of subjects: 30
Study 15640607 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 50 microg sublingually
Number of subjects: 160
Study 15640607 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol 50 microg vaginally
Number of subjects: 160
Study 12523454 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental conditions (specifics not provided)
Number of subjects: 0
Study 12523454 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (specifics not provided)
Number of subjects: 0
Study 10695094 — intervention group
Group type: EXPERIMENTAL
Intervention: amoxycillin/clavulanate 875/125 mg twice daily
Number of subjects: 324
Study 10695094 — intervention group
Group type: COMPARATOR
Intervention: amoxycillin/clavulanate 500/125 mg three times daily
Number of subjects: 324
Study 8620702 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY u3405 (75 mg orally, twice a day for 2 weeks)
Number of subjects: 12
Study 8620702 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral, twice a day for 2 weeks)
Number of subjects: 12
Study 2008870 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acid (MUFA) diet
Number of subjects: 26
Study 2008870 — intervention group
Group type: COMPARATOR
Intervention: Polyunsaturated fatty acid (PUFA) diet
Number of subjects: 26
Study 6285241 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide monotherapy
Number of subjects: 55
Study 6285241 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide + CCNU
Number of subjects: 55
Study 6285241 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic therapy (control group)
Number of subjects: 55
Study 29986592 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace intervention targeting sedentary behavior
Number of subjects: 632
Study 29986592 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey sent to nonparticipants (N = 57)
Number of subjects: 632
Study 29986592 — intervention group
Group type: EXPERIMENTAL
Intervention: Modifications developed to overcome participation barriers
Number of subjects: 632
Study 27830365 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (5 mg) administered daily during postoperative days 0-5
Number of subjects: 201
Study 27830365 — intervention group
Group type: COMPARATOR
Intervention: Control group (no haloperidol)
Number of subjects: 201
Study 24977456 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention
Number of subjects: 40
Study 24977456 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 40
Study 23403068 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin (5 mg/day)
Number of subjects: 2258
Study 23403068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2258
Study 23403068 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 2258
Study 22000309 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (20 mg/kg)
Number of subjects: 100
Study 22000309 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin (20 mg/kg)
Number of subjects: 100
Study 22000309 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (20 mg/kg) with diazepam
Number of subjects: 100
Study 22000309 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin (20 mg/kg) with diazepam
Number of subjects: 100
Study 22000309 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate only
Number of subjects: 100
Study 22000309 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin only
Number of subjects: 100
Study 22000309 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate and Phenytoin
Number of subjects: 100
Study 19016706 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacalcitol ointment plus sunlight exposure
Number of subjects: 80
Study 19016706 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo) ointment plus sunlight exposure
Number of subjects: 80
Study 17442583 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive paper-tape closure
Number of subjects: 60
Study 17442583 — intervention group
Group type: COMPARATOR
Intervention: Sutured closure
Number of subjects: 60
Study 15574550 — intervention group
Group type: EXPERIMENTAL
Intervention: MPT (Microcuff pediatric tracheal tube) with baseline cuff pressure set to sealing pressure (10 cm H(2)O)
Number of subjects: 30
Study 15574550 — intervention group
Group type: COMPARATOR
Intervention: PVC (standard polyvinyl chloride cuff) with baseline cuff pressure 20 cm H(2)O
Number of subjects: 30
Study 15574550 — intervention group
Group type: COMPARATOR
Intervention: MPT (Microcuff pediatric tracheal tube) with baseline cuff pressure 20 cm H(2)O
Number of subjects: 30
Study 11422014 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinistrin (2500 mg, intravenous)
Number of subjects: 12
Study 11422014 — intervention group
Group type: EXPERIMENTAL
Intervention: p-Aminohippuric acid (PAH; 440 mg, intravenous)
Number of subjects: 12
Study 11422014 — intervention group
Group type: EXPERIMENTAL
Intervention: Rac-pindolol (15 mg, oral)
Number of subjects: 12
Study 11422014 — intervention group
Group type: EXPERIMENTAL
Intervention: S-pindolol (15 mg, oral)
Number of subjects: 12
Study 11422014 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (100 mg, oral)
Number of subjects: 12
Study 10772561 — intervention group
Group type: EXPERIMENTAL
Intervention: H-ELISA
Number of subjects: 1332
Study 8536521 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of CCK (24 pmol/kg/hr)
Number of subjects: 10
Study 8536521 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 10
Study 15236012 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine
Number of subjects: 34
Study 15236012 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular pethidine
Number of subjects: 34
Study 15236012 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 34
Study 6990334 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment with antimicrobials (cefamandole) starting preoperatively and continuing for 4 days
Number of subjects: 337
Study 6990334 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (treatment only if infection was apparent)
Number of subjects: 337
Study 31091248 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingroup‐slanted inflow of information
Number of subjects: 0
Study 28257735 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium intermaxillary elastics
Number of subjects: 52
Study 28257735 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy intermaxillary elastics
Number of subjects: 52
Study 28257735 — intervention group
Group type: COMPARATOR
Intervention: All elastics
Number of subjects: 52
Study 28257735 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy elastics
Number of subjects: 52
Study 28257735 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium elastics
Number of subjects: 52
Study 26083700 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpine skiing intervention for 12 weeks
Number of subjects: 0
Study 23728174 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (subcutaneous injection for 12 months)
Number of subjects: 45
Study 23728174 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 45
Study 19663929 — intervention group
Group type: EXPERIMENTAL
Intervention: Altitude of 3500 m and higher
Number of subjects: 19
Study 19663929 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing altitude
Number of subjects: 19
Study 19663929 — intervention group
Group type: EXPERIMENTAL
Intervention: Altitude (all levels)
Number of subjects: 19
Study 19663929 — intervention group
Group type: EXPERIMENTAL
Intervention: Altitude (3500 m and higher)
Number of subjects: 19
Study 19663929 — intervention group
Group type: EXPERIMENTAL
Intervention: Altitude
Number of subjects: 19
Study 18617745 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic intervention (45 min every other week)
Number of subjects: 41
Study 18617745 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound (12 min once a week for 10 weeks)
Number of subjects: 41
Study 12788888 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 implant of MENT (400 microg/d x implant)
Number of subjects: 16
Study 12788888 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 implants of MENT (400 microg/d x implant)
Number of subjects: 16
Study 10825322 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl infusion at 1.5 ng/mL
Number of subjects: 60
Study 10825322 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl infusion at 3.0 ng/mL
Number of subjects: 60
Study 10825322 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl infusion at 4.5 ng/mL
Number of subjects: 60
Study 10825322 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (Control)
Number of subjects: 60
Study 10825322 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative IV patient-controlled analgesia fentanyl
Number of subjects: 60
Study 8996955 — intervention group
Group type: EXPERIMENTAL
Intervention: Education group (individual education programme lasting at least one hour)
Number of subjects: 60
Study 8996955 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 60
Study 8996955 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 1737255 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium pamidronate
Number of subjects: 0
Study 6363158 — intervention group
Group type: EXPERIMENTAL
Intervention: Diproderm cream 0.05%, applied twice a day
Number of subjects: 0
Study 6363158 — intervention group
Group type: COMPARATOR
Intervention: Diproderm cream 0.05%, applied once a day
Number of subjects: 0
Study 30597580 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio Tactile Performance (ATP) technique
Number of subjects: 0
Study 30597580 — intervention group
Group type: COMPARATOR
Intervention: Braille and audio aids (Control)
Number of subjects: 0
Study 29975723 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention video (basic response to a hospital fire)
Number of subjects: 128
Study 29975723 — intervention group
Group type: COMPARATOR
Intervention: Control video (introduction to volcanic disasters)
Number of subjects: 128
Study 27015260 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling for HPV and results counseling
Number of subjects: 94
Study 27015260 — intervention group
Group type: COMPARATOR
Intervention: Information-only group
Number of subjects: 94
Study 27015260 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling for HPV
Number of subjects: 94
Study 24629400 — intervention group
Group type: EXPERIMENTAL
Intervention: Central systolic blood pressure (SBP)
Number of subjects: 57
Study 24629400 — intervention group
Group type: EXPERIMENTAL
Intervention: Central diastolic blood pressure (DBP)
Number of subjects: 57
Study 24629400 — intervention group
Group type: EXPERIMENTAL
Intervention: Central pulse pressure variability
Number of subjects: 57
Study 24629400 — intervention group
Group type: EXPERIMENTAL
Intervention: Central augmented pressure
Number of subjects: 57
Study 22795613 — intervention group
Group type: COMPARATOR
Intervention: IV morphine alone
Number of subjects: 40
Study 22795613 — intervention group
Group type: EXPERIMENTAL
Intervention: IV morphine and IV oxycodone (0.75 mg each)
Number of subjects: 40
Study 22795613 — intervention group
Group type: EXPERIMENTAL
Intervention: IV morphine plus IV oxycodone (0.5 mg/0.5 mg) via PCA
Number of subjects: 40
Study 22795613 — intervention group
Group type: COMPARATOR
Intervention: 1 mg IV morphine alone via PCA
Number of subjects: 40
Study 20542087 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) representation in a ReaCTor
Number of subjects: 0
Study 20542087 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D computer screen (conventional neurofeedback medium)
Number of subjects: 0
Study 20542087 — intervention group
Group type: COMPARATOR
Intervention: No-training comparison group
Number of subjects: 0
Study 18090745 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic reviews
Number of subjects: 0
Study 18090745 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis
Number of subjects: 0
Study 18090745 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled clinical trials
Number of subjects: 0
Study 17519714 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 ml 0.75% ropivacaine
Number of subjects: 70
Study 17519714 — intervention group
Group type: COMPARATOR
Intervention: 2.5 ml 2% lidocaine
Number of subjects: 70
Study 15009349 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for MCHN in identification and management of distressed mothers, including access to a liaison psychiatric network for consultation and referrals.
Number of subjects: 40
Study 15009349 — intervention group
Group type: COMPARATOR
Intervention: Standard management services provided by control group nurses.
Number of subjects: 40
Study 10971240 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg
Number of subjects: 12
Study 10971240 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 12
Study 10971240 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 12
Study 10971240 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 7.5 mg
Number of subjects: 12
Study 10971240 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 10 mg
Number of subjects: 12
Study 9083904 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine digluconate mouthwash
Number of subjects: 121
Study 9083904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 8451009 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame 600 mg
Number of subjects: 18
Study 8451009 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame 1200 mg
Number of subjects: 18
Study 8451009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3082175 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 29
Study 3082175 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocainide
Number of subjects: 29
Study 31317843 — intervention group
Group type: EXPERIMENTAL
Intervention: Radically Open Dialectical Behaviour Therapy (RO DBT) plus Treatment as Usual (TAU)
Number of subjects: 250
Study 31317843 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 250
Study 31317843 — intervention group
Group type: EXPERIMENTAL
Intervention: Radically Open Dialectical Behaviour Therapy (RO DBT)
Number of subjects: 250
Study 31127381 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept injections alone (Group A)
Number of subjects: 51
Study 31127381 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept injections followed by micropulsed laser (Group B)
Number of subjects: 51
Study 31127381 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 51
Study 27566242 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow aspirate concentrate (BMAC)
Number of subjects: 25
Study 27566242 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 25
Study 25817883 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading (final prosthesis delivered within 24 hours)
Number of subjects: 15
Study 25817883 — intervention group
Group type: COMPARATOR
Intervention: Delayed loading
Number of subjects: 15
Study 24706354 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral conjoint therapy for PTSD
Number of subjects: 40
Study 24706354 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 40
Study 21823174 — intervention group
Group type: EXPERIMENTAL
Intervention: Group music intervention using percussion instruments with familiar music, 30-min sessions, twice weekly for 6 weeks
Number of subjects: 60
Study 21823174 — intervention group
Group type: COMPARATOR
Intervention: Usual care with no music intervention
Number of subjects: 60
Study 19326141 — intervention group
Group type: EXPERIMENTAL
Intervention: HYPOXIC (F(I)O(2) = 0.15)
Number of subjects: 0